6-(((tert-butyldimethylsilyl)oxy)methyl)-2,2,3,3,9,9,10,10-octamethyl-4,8-dioxa-3,9-disilaundecan-6-amine | 102522-47-4

• 分子结构分类: 有机化合物 - 有机金属化合物 - 有机类金属化合物
• 英文名称: 6-(((tert-butyldimethylsilyl)oxy)methyl)-2,2,3,3,9,9,10,10-octamethyl-4,8-dioxa-3,9-disilaundecan-6-amine
• 英文别名: 2-(tert-Butyl-dimethyl-silanyloxy)-1,1-bis-(tert-butyl-dimethyl-silanyloxymethyl)-ethylamine；1,3-bis[[tert-butyl(dimethyl)silyl]oxy]-2-[[tert-butyl(dimethyl)silyl]oxymethyl]propan-2-amine
• CAS: 102522-47-4
• 化学式: C₂₂H₅₃NO₃Si₃
• 分子量: 463.924
• InChiKey: VPKYOQBACGWZCO-UHFFFAOYSA-N

物化性质

• 熔点：
  32-34 °C
• 沸点：
  431.6±45.0 °C(Predicted)
• 密度：
  0.888±0.06 g/cm3(Predicted)
• 溶解度：
  溶于DMSO、DCM、DMF

计算性质

• 辛醇/水分配系数(LogP)：
  6.75
• 重原子数：
  29
• 可旋转键数：
  12
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  53.7
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 危险性防范说明：
  P264,P280,P302+P352,P337+P313,P305+P351+P338,P362+P364,P332+P313
• 危险性描述：
  H315,H319
• 储存条件：
  存储条件为2-8°C，避光，并在惰性气体环境中保存。

反应信息

• 作为反应物：
  描述：

  6-(((tert-butyldimethylsilyl)oxy)methyl)-2,2,3,3,9,9,10,10-octamethyl-4,8-dioxa-3,9-disilaundecan-6-amine 在 哌啶 、 1-羟基苯并三唑 、 N,N'-二环己基碳二亚胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 生成 (2S)-2-amino-N-[1,3-bis[[tert-butyl(dimethyl)silyl]oxy]-2-[[tert-butyl(dimethyl)silyl]oxymethyl]propan-2-yl]-3-(1-tritylimidazol-4-yl)propanamide
  参考文献：
  名称：

  A novel bleomycin model compound bearing hydrophilic steric factor exhibited high oxygen activating capacity

  摘要：

  DOI：

  10.1016/00404-0399(50)1064o-
• 作为产物：
  描述：

  tris(tert-butyldimethylsilyloxymethyl)nitromethane 在 镍 一水合肼 作用下， 以 甲醇 为溶剂， 以90%的产率得到6-(((tert-butyldimethylsilyl)oxy)methyl)-2,2,3,3,9,9,10,10-octamethyl-4,8-dioxa-3,9-disilaundecan-6-amine
  参考文献：
  名称：

  Gansey, Marcel H. B. Grote; Steemers, Frank J.; Verboom, Willem, Synthesis, 1997, # 6, p. 643 - 648

  摘要：

  DOI：

文献信息

• End group engineering of artificial ion channels
  作者：François Otis、Normand Voyer、Ange Polidori、Bernard Pucci

  DOI：10.1039/b509668e

  日期：——

  Toward developing nanostructures for single molecule detection, we report the synthesis of new derivatives of artificial devices that possess ion channel activity. The membrane stability and the ion transport ability of these multiple crown α-helical peptides have been optimized by modulating the polarity of N- and C-terminal groups with incorporation of hydrophilic non-ionic units. Circular dichroism and ATR studies confirmed the α-helical conformation and membrane incorporation of new nanostructures while 23Na NMR assays shown a significant increase of their ion transport ability.

  在开发用于单分子检测的纳米结构方面，我们报道了具有离子通道活性的人造设备的新衍生物的合成。通过在N端和C端基团中加入亲水性非离子单元来调节极性，已经优化了这些多重冠状α螺旋肽的膜稳定性和离子传输能力。圆二色散和ATR研究表明，这些新纳米结构具有α螺旋构象并整合入膜，而23Na NMR测试显示它们的离子传输能力显著提高。
• [EN] CARBON MONOXIDE RELEASING NORBORNENONE COMPOUNDS<br/>[FR] COMPOSÉS DE NORBORNÉNONE LIBÉRANT DU MONOXYDE DE CARBONE
  申请人：SAMMUT IVAN ANDREW

  公开号：WO2017095237A1

  公开（公告）日：2017-06-08

  The present invention provides organic compounds which are capable of releasing carbon monoxide under physiological conditions or pH trigger, and to the use of such compounds for conditioning a cell, tissue or organ, for example, to protect against ischaemic injury during a transplant event.

  本发明提供了在生理条件或pH触发下能够释放一氧化碳的有机化合物，以及将这种化合物用于调节细胞、组织或器官，例如，在移植事件中保护免受缺血性损伤的使用方法。
• [EN] CATIONIC LIPIDS<br/>[FR] LIPIDES CATIONIQUES
  申请人：UNIV EDINBURGH

  公开号：WO2009050483A1

  公开（公告）日：2009-04-23

  This invention relates to cationic lipids. More particularly the invention relates to biodegradable cationic lipids having a plurality of cationic headgroups and one or more lipophilic tail groups. The lipids are of utility in various applications, and in particular in permitting transfection of molecules, and in particular DNA and RNA, into cells. As such the lipids have specific utility in the field of gene therapy as well as other applications such as delivery of small molecules into cells, detergents, and metal ion complexation for medical or industrial applications.

  这项发明涉及阳离子脂质。更具体地，该发明涉及具有多个阳离子头基和一个或多个亲脂尾基的可生物降解阳离子脂质。这些脂质在各种应用中具有实用性，特别是在允许分子转染，特别是DNA和RNA，进入细胞方面。因此，这些脂质在基因治疗领域以及其他应用中具有特定的实用性，如将小分子输送到细胞中、洗涤剂以及医疗或工业应用中的金属离子络合。
• [EN] POLYNUCLEOTIDE CONSTRUCTS HAVING DISULFIDE GROUPS<br/>[FR] CONSTRUCTIONS POLYNUCLÉOTIDIQUES CONTENANT DES GROUPES DISULFURE
  申请人：SOLSTICE BIOLOG LTD

  公开号：WO2015069932A1

  公开（公告）日：2015-05-14

  The invention features polynucleotide constructs containing one or more components (i) containing a disulfide linkage, where each of the one or more components is attached to an internudeotide bridging group or a terminal group of the polynucleotide construct, and each of the one or more components (i) contains one or more bulky groups proximal to the disulfide group. The invention also features polynucleotide constructs containing one or more components (i) containing a disulfide linkage, where each of the one or more components (i) is attached to an internudeotide bridging group or a terminal group of the polynucleotide construct, and each of the one or more components (i) contains at least 4 atoms in a chain between the disulfide linkage and the phosphorus atom of the internudeotide bridging group or the terminal group; and where the chain does not contain a phosphate, an amide, an ester, or an alkenylene. The invention also features methods of delivering a polynucleotide to a cell using the polynucleotide constructs of the invention.

  该发明涉及包含一个或多个组分（i）的聚核苷酸构造，其中每个一个或多个组分连接到聚核苷酸构造的一个核苷酸桥连基团或末端基团上，每个一个或多个组分（i）包含靠近二硫键的一个或多个臃肿基团。该发明还涉及包含一个或多个组分（i）的聚核苷酸构造，其中每个一个或多个组分（i）连接到聚核苷酸构造的一个核苷酸桥连基团或末端基团上，每个一个或多个组分（i）在二硫键和核苷酸桥连基团或末端基团的磷原子之间的链中至少包含4个原子；并且该链不包含磷酸酯、酰胺、酯或烯基烃。该发明还涉及使用该发明的聚核苷酸构造将聚核苷酸传递到细胞的方法。
• [EN] HYDROXY FORMAMIDE DERIVATIVES AND THEIR USE<br/>[FR] DÉRIVÉS D'HYDROXY FORMAMIDE ET LEUR UTILISATION
  申请人：GLAXOSMITHKLINE IP NO 2 LTD

  公开号：WO2015104684A1

  公开（公告）日：2015-07-16

  Disclosed are compounds having the formula (I): wherein R1, R2 and R3 are as defined herein, and methods of making and using the same, including use as inhibitors of BMP1, TLL1 and/or TLL2 and in treatment of diseases associated with BMP1, TLL1 and/or TLL2 activity.

  揭示了具有以下化学式（I）的化合物：其中R1、R2和R3如本文所定义，并且制备和使用这些化合物的方法，包括用作BMP1、TLL1和/或TLL2的抑制剂以及用于治疗与BMP1、TLL1和/或TLL2活性相关的疾病。